Ye Dingde, Qu Jiamu, Wang Jian, Li Guoqiang, Sun Beicheng, Xu Qingxiang
Medicine School of Southeast University Nanjing Drum Tower Hospital, Nanjing, China.
Nanjing Medical University, Nanjing, China.
Front Oncol. 2021 Sep 6;11:698980. doi: 10.3389/fonc.2021.698980. eCollection 2021.
Hepatocellular carcinoma is a common malignant tumor of the digestive system with a poor prognosis. The high recurrence rate and metastasis after surgery reduce the survival time of patients. Therefore, assessing the overall survival of patients with hepatocellular carcinoma after hepatectomy is critical to clinicians' clinical decision-making. Conventional hepatocellular carcinoma assessment systems (such as tumor lymph node metastasis and Barcelona clinical hepatocellular carcinoma) are obviously insufficient in assessing the overall survival rate of patients. This research is devoted to the development of nomogram assessment tools to assess the overall survival probability of patients undergoing liver resection.
We collected the clinical and pathological information of 438 hepatocellular carcinoma patients undergoing surgery from The Cancer Genome Atlas (TCGA) database, then excluded 87 patients who did not meet inclusion criteria. Univariate and multivariate analyses were performed on patient characteristics and related pathological factors. Finally, we developed a nomogram model to predict patient's prognosis.
A retrospective analysis of 438 consecutive samples from the TCGA database of patients with hepatocellular carcinoma who underwent potentially curative liver resections. Six risk factors were included in the final model. In the training set, the discriminative ability of the nomogram was very good (concordance index = 0.944), and the external verification method (concordance index = 0.962) was used for verification. At the same time, the internal and external calibration of the model was verified, showing that the model was well calibrated. The calibration between the evaluation of the nomogram and the actual observations was good. According to the patient's risk factors, we determined the patient's Kaplan-Meyer survival analysis curve. Finally, the clinical decision curve was used to compare the benefits of two different models in evaluating patients' clinical outcomes.
The nomogram can be used to evaluate the post-hepatectomy 1-, 3-, and 5-year survival rates of patients with hepatocellular carcinoma. The Kaplan-Meyer curve can intuitively display the survival differences among patients with various risk factors. The clinical decision curve is a good reference guide for clinical application.
肝细胞癌是消化系统常见的恶性肿瘤,预后较差。术后高复发率和转移率降低了患者的生存时间。因此,评估肝切除术后肝细胞癌患者的总生存期对临床医生的临床决策至关重要。传统的肝细胞癌评估系统(如肿瘤淋巴结转移和巴塞罗那临床肝癌)在评估患者总生存率方面明显不足。本研究致力于开发列线图评估工具,以评估肝切除患者的总生存概率。
我们从癌症基因组图谱(TCGA)数据库收集了438例接受手术的肝细胞癌患者的临床和病理信息,然后排除了87例不符合纳入标准的患者。对患者特征和相关病理因素进行单因素和多因素分析。最后,我们开发了一个列线图模型来预测患者的预后。
对来自TCGA数据库的438例接受潜在根治性肝切除的肝细胞癌患者的连续样本进行回顾性分析。最终模型纳入了六个危险因素。在训练集中,列线图的判别能力非常好(一致性指数=0.944),并采用外部验证方法(一致性指数=0.962)进行验证。同时,对模型的内部和外部校准进行了验证,表明模型校准良好。列线图评估与实际观察之间的校准良好。根据患者的危险因素,我们确定了患者的Kaplan-Meier生存分析曲线。最后,使用临床决策曲线比较两种不同模型在评估患者临床结局方面的益处。
列线图可用于评估肝细胞癌患者肝切除术后1年、3年和5年生存率。Kaplan-Meier曲线可以直观地显示不同危险因素患者之间的生存差异。临床决策曲线是临床应用的良好参考指南。